From Wikipedia, the free encyclopedia
|This article needs additional or better citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. (November 2012) (Learn how and when to remove this template message)|
|Chemical and physical data|
|Molar mass||151 kg/mol|
Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGLF2. It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.
- Statement On A Nonproprietary Name Adopted By The USAN Council - Dusigitumab, American Medical Association.
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|